Alpa laboratories has issued a clarification to stock exchanges regarding recent price movement in its shares, confirming that there is no undisclosed price sensitive information affecting the company's performance.

Stock Exchange Communication

In response to an inquiry dated April 8, 2026, from stock exchanges regarding price movement in the company's stock, Alpa Laboratories submitted its clarification on April 9, 2026. The communication was addressed to both the Bombay Stock Exchange and National Stock Exchange of India Ltd.

Company's Clarification

The pharmaceutical company stated that there is no information or event that would have a bearing on the company's performance, confirming that no price sensitive information has been withheld from disclosure. Director Mahendra Singh Chawla emphasized that the company does not have any announcement in the near future which may impact the price or volume of its scrip.

Regulatory Compliance

The clarification was issued under Regulation 30 of securities regulations, which requires listed companies to disclose material events and information that could affect stock prices. The company's proactive response demonstrates adherence to disclosure norms and transparency requirements for listed entities.

The communication serves to address any market speculation regarding the stock's price movement and reaffirms the company's commitment to timely disclosure of material information to investors and regulatory authorities.

Alpa Laboratories Limited has submitted comprehensive disclosures to stock exchanges regarding a share transfer transaction between promoter group members under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction involved the transfer of 21,940 equity shares as a gift between immediate relatives of the promoter group on March 7, 2026.

Transaction Overview

The share transfer involved Mr. Vinit Shah acquiring equity shares from Bakulesh Chandulal Shah HUF through an off-market inter se transfer by way of gift. The transaction details are summarized below:

Shareholding Changes

The transaction resulted in a complete transfer of shareholding between the two parties, with no net change in promoter group holdings:

Regulatory Compliance Framework

The company has filed comprehensive disclosures with both National Stock Exchange of India Limited and Bombay Stock Exchange Limited under multiple regulations:

The transaction is exempt from open offer requirements under Regulation 10(1)(a)(i) of SEBI (SAST) Regulations, 2011, as it involves transfer between immediate relatives of promoter group members. Both parties have confirmed their status as part of the promoter/promoter group of Alpa Laboratories Limited.

Company Statement and Compliance

Alpa Laboratories Limited has confirmed through Company Secretary Prashiti Chopra that there is no change in the total shareholding of promoter and promoter group of the company pre and post transfer of shares. The company has requested stock exchanges to update their records with the disclosed information for compliance purposes.

All disclosures were signed and dated March 7, 2026, from Indore, with Mr. Vinit Shah signing as the acquirer and Bakulesh Shah signing as Karta of Bakulesh Chandulal Shah HUF for the disposal transaction. The company maintains its equity share capital at 21,040,600 shares with no dilution effect from this inter se transfer.